Aratana Therapeutics (PETX) Issues Encouraging Update on ADXS31-164 in Spontaneous Osteosarcoma
Tweet Send to a Friend
Aratana Therapeutics (Nasdaq: PETX) provided commentary on clinical study data involving ADXS31-164 (AT-014) that was recently presented during a poster ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
